Company Encyclopedia
View More
name
abrdn Healthcare Investors
HQH.US
News
View More

HSBC turns more bullish on Amgen (AMGN) into 2026

HSBC has increased its price target for Amgen Inc. (NASDAQ:AMGN) from $381 to $425, maintaining a Buy rating. This adjustment is part of HSBC's 2026 outlook for the pharmaceutical sector, where Amgen is highlighted as one of the 12 Best Dogs of the Dow to invest in.

MSN·
US
AMGN
-0.17%
MSN·
US
AMGN
-0.17%

Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.

Eli Lilly's stock has significantly outperformed Nvidia's recently, with a 30% rise compared to Nvidia's 14% loss since Oct. 29. DataTrek analyst Jessica Rabe notes that historically, Nvidia tends to modestly outperform Eli Lilly over the next two months after such deviations. However, the likelihood of Nvidia outperforming is less than 50%. The broader healthcare sector has also outperformed tech, but history suggests tech may rebound in the next two months. Recent market actions show continued tech underperformance.

Dow Jones·
US
LLY
-1.22%
Dow Jones·
US
LLY
-1.22%

Promising Pharmaceutical Stocks To Watch Now - December 17th

MarketBeat's stock screener highlights Eli Lilly, Pfizer, and AbbVie as key pharmaceutical stocks to watch. These companies are involved in developing and marketing drugs, offering potential revenue from drug approvals and sales. However, they also carry risks related to regulations and patents. Despite Eli Lilly's current Buy rating, top analysts suggest other stocks may offer better investment opportunities.

Market Beat·
US
LLY
-1.22%
US
ABBV
+0.66%
Market Beat·
US
LLY
-1.22%
US
ABBV
+0.66%

10:06 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Inspire Medical Systems

Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. for allegedly making false statements about the market demand and launch of its Inspire V device. The company faced setbacks, including training delays and billing issues, leading to a significant stock price drop. Investors are encouraged to contact the firm to discuss legal options before the January 5, 2026 deadline for a federal securities class action.

prnewswire·
US
INSP
+2.43%
prnewswire·
US
INSP
+2.43%

Woodstock Corp Acquires 8,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Woodstock Corp increased its stake in Regeneron Pharmaceuticals by 107.1% in Q3, owning 16,610 shares worth $9,339,000. Other investors also adjusted their positions in REGN. Insider sales included Director Christine A. Poon and VP Jason Pitofsky. Analysts issued new price targets, with a consensus rating of "Moderate Buy" and an average price target of $779.45. REGN stock opened at $746.36, with a 12-month low of $476.49 and high of $790.98.

Market Beat·
US
REGN
+0.41%
Market Beat·
US
REGN
+0.41%
© 2025 Longbridge｜Disclaimer